Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
Authors Buehler A
Received 21 November 2014
Accepted for publication 24 November 2014
Published 8 January 2015 Volume 2015:9 Pages 419—423
Checked for plagiarism Yes
Editor who approved publication: Professor Shu-Feng Zhou
Anna M Buehler
Hospital Alemao Oswaldo Cruz, Institute of Health Education and Sciences, Sao Paulo, Brazil
I read with great interest the systematic review by Caixàs et al1 on the effect of naltrexone sustained-release/bupropion sustained-release (NB) for the management of obesity. By comprehensively appraising five recent clinical trials, the authors concluded that the naltrexone/bupropion combination might represent an important new therapeutic option for the management of obesity, with a weight reduction effect that is similar to other drugs approved for the treatment of obesity.
View original paper by Caixàs and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]